Research and Reviews - International Journals

Research & Reviews: Journal of Pharmacology and Toxicological Studies

Menu

e-ISSN: 2322-0139 p-ISSN: 2322-0120

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Short Review on Dapagliflozin

Vishnu Vardhan*

Department of Biotechnology, Gokaraju Rangaraju Institute of Engineering and Technology, Bachupally, Kukatpally, Hyderabad, Telangana, India

*Corresponding Author:
Vishnu Vardhan
Department of Biotechnology, Gokaraju Rangaraju Institute of Engineering and Technology
Bachupally, Kukatpally, Hyderabad, Telangana, India
Tel: +91 9888484451.
E-mail: vishnupannala80@gmail.com

Received date: 26/11/2016; Revised date: 02/12/2016; Accepted date: 07/12/2016

Visit for more related articles at Research & Reviews: Journal of Pharmacology and Toxicological Studies

Research & Reviews: Journal of Pharmacology and Toxicological Studies

Abstract

Dapagliflozin is a medication of the gliflozin class, used to treat type 2 diabetes. It was produced by Bristol-Myers Squibb in organization with AstraZeneca. Dapagliflozin is a sodium-glucose cotransporter 2(SGLT2) inhibitor. It works by diminishing the measure of sugar the body assimilates and expanding the measure of sugar that leaves the body. Dapagliflozin is utilized alongside diet and work out, and now and again with different drugs, to lower glucose levels in patients with type 2 diabetes (condition in which glucose is too high in light of the fact that the body does not create or utilize insulin ordinarily). Dapagliflozin is in a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It brings down glucose by creating the kidneys to dispose of more glucose. Dapagliflozin is not used to treat type 1 diabetes (condition in which the body does not deliver insulin and, in this manner, can't control the measure of sugar in the blood) or diabetic ketoacidosis (a genuine condition that may create if high glucose is not treated).

Keywords

Dapagliflozin, Cotransporter, Hypoglycaemia

Introduction

After some time, individuals who have diabetes and high glucose can create genuine or life-debilitating confusions, including coronary illness, stroke, kidney issues, nerve harm, and eye issues. Taking Dapagliflozin, rolling out way of life improvements (e.g., abstain from food, work out, stopping smoking), and consistently checking your glucose may deal with your diabetes and enhance your wellbeing. This treatment may likewise diminish your odds of showing at least a bit of kindness assault, stroke, or different diabetes-related complexities, for example, kidney disappointment, nerve harm (numb, chilly legs or feet; diminished sexual capacity in men and ladies), eye issues, including changes or loss of vision, or gum infection [1-9].

Structure Of Dapagliflozin

Dapagliflozin comes as a tablet to take by mouth. It is brought as a rule with or without sustenance once per day in the morning. Take Dapagliflozin at around a similar time each day. Take after the headings on your solution name painstakingly, and ask your specialist or drug specialist to clarify any part you don't get it. Take Dapagliflozin precisely as coordinated [10-18]. Try not to take pretty much of it or take it more regularly than recommended by your specialist.

Repressing renal glucose reabsorbtion through the sodium-glucose cotransporter (SGLT) offers an insulin-free contrasting option to controlling blood glucose focuses in patients with type 2 diabetes. While the larger part of glucose is reabsorbed from glomerular filtrate by SGLT2, which is overwhelmingly communicated in the kidney S1 portion of the proximal tubule, SGLT1 reabsorbs glucose in the distal S3 fragment of the renal proximal tubule and in addition from the small digestive system. Dapagliflozin is an original, particular SGLT inhibitor that squares glucose transport with around 100-overlay selectivity for SGLT2 (Ki = 6 nM; EC50 = 1.1 nM) over SGLT1 (Ki = 390 nM). After single oral measurements extending from 0.1 to 1.0 mg/kg, Dapagliflozin increments urinary glucose discharge in both ordinary and diabetic rats, enhances glucose resistance in typical rats, and lessens hyperglycemia in Zucker diabetic greasy rats. Within two weeks of treating diabetic rats with 0.1 to 1.0 mg/kg Dapagliflozin, fasting and encouraged glucose levels have been appeared to be altogether brought down as a consequence of expanded glucose use joined by decreased glucose production [19-28].

Dapagliflozin 3-O-glucuronide is the essential metabolite of Dapagliflozin, with 61% of the Dapagliflozin dosage recouped in the pee as this metabolite. The digestion system of Dapagliflozin is principally intervened by UGT1A9-subordinate glucuronide conjugation. The significant metabolite, Dapagliflozin 3-O-glucuronide, is not a SGLT2 inhibitor.

Dapagliflozin comes as a tablet to take by mouth. It is brought ordinarily with or without sustenance once every day in the morning. Take Dapagliflozin at around a similar time each day. Take after the bearings on your medicine name painstakingly, and ask your specialist or drug specialist to clarify any part you don't get it. Take Dapagliflozin precisely as coordinated. Try not to take pretty much of it or take it more frequently than endorsed by your specialist [29-37].

Toxicity

Contrasted with fake treatment treated patients, patients with direct renal debilitation treated with Dapagliflozin did not have change in glycemic control and had more renal-related antagonistic responses and more bone cracks; accordingly, Dapagliflozin ought not to be started in this populace. In view of its component of activity, Dapagliflozin is not anticipated that would be viable in patients with serious renal impedance (eGFR under 30 mL/min/1.73 m2) or ESRD [38-49].

Dapagliflozin may cause serious side effects including:

Drying out (the loss of body water and salt), which may make you feel bleary eyed, swoon, woozy, or powerless, particularly when you stand up (orthostatic hypotension). You might be at a higher danger of lack of hydration in the event that you have low circulatory strain; take prescriptions to bring down your pulse, including water pills (diuretics); are 65 years old or more established; are on a low salt eating routine, or have kidney issues [50-61].

Ketoacidosis happened in individuals with type 1 and type 2 diabetes amid treatment with dapagliflozin. Ketoacidosis is a genuine condition which may require hospitalization and may prompt to death. Indications may incorporate queasiness, tiredness, spewing, inconvenience breathing, and stomach torment. In the event that you get any of these side effects, quit accepting dapagliflozin and summon your human services supplier right. In the event that conceivable, check for ketones in your pee or blood, regardless of the possibility that your glucose is under 250 mg/dL [62-67].

Kidney issues, sudden kidney harm happened in individuals taking dapagliflozin. Converse with your specialist immediately in the event that you decrease the sum you eat or drink, or on the off chance that you lose fluids; for instance, from regurgitating, the runs, or extreme warmth introduction [68-70].

Genuine urinary tract diseases (UTI), some that prompt to hospitalization, happened in individuals taking dapagliflozin. Tell your specialist on the off chance that you have any signs or indications of UTI including a smoldering feeling when passing pee, a need to urinate frequently, the need to urinate immediately, torment in the lower a portion of your stomach (pelvis), or blood in the pee with or without fever, back agony, sickness, or regurgitating [71-76].

Low glucose (hypoglycaemia) can happen in the event that you bring dapagliflozin with another drug that can bring about low glucose, for example, sulfonylureas or insulin. Side effects of low glucose incorporate shaking, sweating, quick pulse, tipsiness, appetite, cerebral pain, and peevishness. Take after your human services supplier's directions for treating low glucose [77-80].

Vaginal yeast contaminations in ladies who take dapagliflozin. Converse with your medicinal services supplier on the off chance that you encounter vaginal smell, white or yellowish vaginal (release might be uneven or look like curds), or vaginal tingling [81-87].

Yeast disease of skin around the penis (balanitis) in men who take dapagliflozin. Converse with your human services supplier on the off chance that you encounter redness, tingling, or swelling of the penis; rash of the penis; noxious release from the penis; or agony in the skin around penis. Certain uncircumcised men may have swelling of the penis that makes it hard to pull back the skin around the tip of the penis [88-95]. Increment in awful cholesterol (LDL-C). Your social insurance supplier ought to check your LDL-C amid treatment with dapagliflozin.

Bladder tumor: In investigations of dapagliflozin in individuals with diabetes, bladder tumor happened in a couple of a bigger number of individuals who were taking dapagliflozin than in individuals who were taking different diabetes medicines [96-102]. There were excessively few instances of bladder tumor, making it impossible to know whether bladder disease was identified with dapagliflozin. Tell your human services supplier immediately on the off chance that you have blood or red shading in faecal matter or agony while you urinate.

References